174 related articles for article (PubMed ID: 26444983)
1. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
2. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
[TBL] [Abstract][Full Text] [Related]
3. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
[TBL] [Abstract][Full Text] [Related]
4. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
Gruen M; Bommert K; Bargou RC
Cancer Immunol Immunother; 2004 Jul; 53(7):625-32. PubMed ID: 15175907
[TBL] [Abstract][Full Text] [Related]
5. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
de Gast GC; Haagen IA; van Houten AA; Klein SC; Duits AJ; de Weger RA; Vroom TM; Clark MR; Phillips J; van Dijk AJ
Cancer Immunol Immunother; 1995 Jun; 40(6):390-6. PubMed ID: 7543021
[TBL] [Abstract][Full Text] [Related]
6. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth B; Quadt C; Dreier T; Kufer P; Lorenczewski G; Prang N; Brandl C; Lippold S; Cobb K; Brasky K; Leo E; Bargou R; Murthy K; Baeuerle PA
Cancer Immunol Immunother; 2006 May; 55(5):503-14. PubMed ID: 16032400
[TBL] [Abstract][Full Text] [Related]
7. Induction of a central memory and stem cell memory phenotype in functionally active CD4
Blaeschke F; Stenger D; Kaeuferle T; Willier S; Lotfi R; Kaiser AD; Assenmacher M; Döring M; Feucht J; Feuchtinger T
Cancer Immunol Immunother; 2018 Jul; 67(7):1053-1066. PubMed ID: 29605883
[TBL] [Abstract][Full Text] [Related]
8. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
9. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
[TBL] [Abstract][Full Text] [Related]
10. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
[TBL] [Abstract][Full Text] [Related]
11. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
Bruserud O
Cancer Immunol Immunother; 1998 Jun; 46(4):221-8. PubMed ID: 9671145
[TBL] [Abstract][Full Text] [Related]
12. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.
Morisaki T; Morton DL; Uchiyama A; Yuzuki D; Barth A; Hoon DS
Cancer Immunol Immunother; 1994 Sep; 39(3):172-8. PubMed ID: 7923247
[TBL] [Abstract][Full Text] [Related]
13. Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.
Smans KA; Hoylaerts MF; De Broe ME
Cancer Immunol Immunother; 1994 Jan; 38(1):43-52. PubMed ID: 8299118
[TBL] [Abstract][Full Text] [Related]
14. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873
[TBL] [Abstract][Full Text] [Related]
15. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
16. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes.
Rabinovich PM; Komarovskaya ME; Wrzesinski SH; Alderman JL; Budak-Alpdogan T; Karpikov A; Guo H; Flavell RA; Cheung NK; Weissman SM; Bahceci E
Hum Gene Ther; 2009 Jan; 20(1):51-61. PubMed ID: 19025415
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody treatment of murine B cell lymphoma.
De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
[TBL] [Abstract][Full Text] [Related]
18. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
[TBL] [Abstract][Full Text] [Related]
20. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.
Ingram W; Kordasti S; Chan L; Barber LD; Tye GJ; Hardwick N; Mufti GJ; Farzaneh F
Cancer Immunol Immunother; 2009 Oct; 58(10):1679-90. PubMed ID: 19283381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]